ArticleBMC cancer2025
Diagnostic value of Gd-EOB-DTPA enhanced MRI in hepatocellular carcinoma with hyperintensity on hepatobiliary phase with cirrhosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the diagnostic value of Gd-EOB-DTPA enhanced MRI in hepatocellular carcinoma (HCC) with hyperintensity on hepatobiliary phase (HBP) under the background of cirrhosis.
methodsA retrospective analysis was conducted on 130 patients diagnosed with cirrhosis and exhibiting hyperintense lesions on HBP in Gd-EOB-DTPA enhanced MRI from January 2015 to December 2022. Of these patients, 56 were diagnosed with hepatocellular carcinoma and 74 had benign cirrhotic nodules. The morphology, signal characteristics, diameter, and ADC value of each lesion were evaluated. Univariate analysis and multivariate logistic regression analysis were performed to determine the independent risk factors of hepatocellular carcinoma and construct a diagnostic model. The diagnostic performance of the model was evaluated using a receiver operating characteristic (ROC) curve.
resultsWe established a diagnostic model by combining the independent risk factors of HCC with hyperintensity on HBP, with an area under the ROC curve of 0.953, sensitivity and specificity were 92.86%、86.49% respectively. Furthermore, a nomogram model for diagnosing hepatocellular carcinoma with HBP hyperintensity was developed and demonstrated good calibration, fitting well with the standard curve.
conclusionIn hepatocellular carcinoma with HBP hyperintensity, the presence of mild-moderate T2-weighted imaging hyperintensity, absence of rim arterial phase hyperenhancement, diffusion-weighted imaging hyperintensity, ADC value ≤ 1.103 × 10− 3mm2/s, and peritumoral hyperintensity on HBP in Gd-EOB-DTPA enhanced MRI can provide valuable diagnostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.